Fekete Z, Rófusz T, Angyal V, Szabó-Révész P, Aigner Z
Analytical Development Department, Generic Research & Development, TEVA Pharmaceutical Works PLC, Táncsics Mihály u. 82, H-2100 Gödöllő, Hungary.
Chemical Control Department, Quality Control Division, TEVA Pharmaceutical Works PLC, Táncsics Mihály u. 82, H-2100 Gödöllő, Hungary.
J Pharm Biomed Anal. 2014 Aug;97:111-5. doi: 10.1016/j.jpba.2014.04.031. Epub 2014 May 2.
Although the opalescence of sterile transparent plastic materials utilized for the packaging of parenteral infusion drugs is a serious quality problem, most suppliers do not report the exact compositions of such polymers, and no literature data are available. Similarly, no information is available as concerns the potential incompatibility of the inner bag and the overpouch. Our gas chromatographic-mass spectrometric study revealed that the cause of the opalescence is the presence of a low-molecular-weight slip additive, 13-docosenamide (erucamide), which is transferred into the primary infusion bag from the overpouch during the heat-sterilization process. Autoclaving trials confirmed the analytical results. In view of these findings, a new slip additive-free overpouch has been produced as secondary packaging material, which does not give rise to opalescence.
尽管用于肠胃外输液药物包装的无菌透明塑料材料出现乳光现象是一个严重的质量问题,但大多数供应商并未报告此类聚合物的确切成分,也没有相关文献数据。同样,关于内袋和外袋潜在的不相容性也没有可用信息。我们的气相色谱 - 质谱研究表明,乳光现象的原因是存在一种低分子量爽滑添加剂,即13 - 二十二碳酰胺(芥酸酰胺),它在热灭菌过程中从外袋转移到主输液袋中。高压灭菌试验证实了分析结果。鉴于这些发现,已生产出一种不含爽滑添加剂的新型外袋作为二级包装材料,该材料不会产生乳光现象。